Interstitial Lung Disease News

The FDA has granted rare pediatric disease designation to Descartes-08, an autologous mRNA cell therapy, for the treatment of juvenile dermatomyositis, Cartesian Therapeutics announced in a press release.

New recommendations from the American College of Rheumatology and the American College of Chest Physicians strongly advise against glucocorticoids for interstitial lung disease in systemic sclerosis.

Former New York Yankees center fielder Bernie Williams is sharing resources for patients with interstitial lung disease as a tribute to his late father, who lost his battle with idiopathic pulmonary fibrosis in 2001.

“Aggressive” combination therapy for gastroesophageal reflux disease improved survival among patients with systemic sclerosis and interstitial lung disease, according to data published in Arthritis Research & Therapy.

Enrollment in the phase 3 VALOR study evaluating brepocitinib for the treatment of dermatomyositis has been completed, Priovant Therapeutics announced in a press release.

Increased body surface area lowered the likelihood for nintedanib dose reduction/discontinuation among patients with fibrotic interstitial lung disease, according to results published in Respiratory Medicine.

Individuals living in medium/small metropolitan and rural areas had increased idiopathic pulmonary fibrosis-related mortality rates vs. those living in large metropolitan areas, according to results published in CHEST.

The risk for mortality was heightened among patients with idiopathic pulmonary fibrosis who experienced more deprivation and lived far from a hospital, according to results published in Respiratory Medicine.

In a study of patients with small cell lung cancer and idiopathic pulmonary fibrosis receiving carboplatin, etoposide and nintedanib, the primary endpoint was met, according to results published in Annals of the American Thoracic Society.